United States Health

IM Cannabis (NASDAQ:IMCC) signed a non-binding letter of intent to acquire 51% of Space Defense Innovations (SDI), a Poland-based company operating in the European unmanned aerial systems market.

ANI Pharmaceuticals (NASDAQ:ANIP) received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Everolimus Tablets for Oral Suspension.

Cardiol Therapeutics (NASDAQ:CRDL) reached its original enrollment target for the Phase III MAVERIC trial of CardiolRx in recurrent pericarditis and plans to expand enrollment to up to 150 patients.

Ionis Pharmaceuticals (NASDAQ:IONS) and Roche reported positive interim results from the Phase 3 IMAgINATION study of sefaxersen in adults with primary IgA nephropathy.

Filana Therapeutics (NASDAQ:FLNA) shares rose after the U.S. Food and Drug Administration lifted a clinical hold on its experimental drug simufilam for epilepsy linked to tuberous sclerosis complex.

Compass Therapeutics (NASDAQ:CMPX) shares declined after the U.S. Food and Drug Administration recommended an additional trial before the company submits a marketing application for tovecimig.

Amgen (NASDAQ:AMGN) said its experimental drug dazodalibep met the primary goal in a late-stage trial evaluating treatment for Sjogren’s disease.

Nutanix (NASDAQ:NTNX) acquired Ryax Technologies, a France-based AI-driven compute orchestration and management platform company, to expand its artificial intelligence infrastructure capabilities.

Celldex Therapeutics (NASDAQ:CLDX) reported positive topline results from two Phase 3 trials evaluating barzolvolimab in adults with chronic spontaneous urticaria.

Vertex Pharmaceuticals (NASDAQ:VRTX) reported positive Phase 2b AMPLIFIED study results for inaxaplin in people with APOL1-mediated kidney disease and different levels of proteinuria.

Ionis Pharmaceuticals (NASDAQ:IONS) and Otsuka Pharmaceutical reported positive topline Phase 3 results for ulefnersen, an investigational RNA-targeted medicine for FUS-ALS.

Ligand Pharmaceuticals (NASDAQ:LGND) agreed to acquire royalty and milestone interests in Santen’s Ryjunea eye drop for a $23 million upfront payment.